Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 2/20 | 0.46 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.44 |
| ▸ | CDK2 | P24941 | 2/20 | 0.44 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.43 |
| ▸ | EP300 | Q09472 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.37 |
| ▸ | CDK1 | P06493 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21325268 | 0.92 | CNR2 (0.46) | CNR2CCNA2CDK2CCNA1MCHR1 | |
| SCHEMBL25466678 | 0.86 | EP300 (0.53) | EP300 | |
| SCHEMBL25466676 | 0.86 | CYP2D6 (0.47) | CNR2MCHR1EP300CNR1 | |
| SCHEMBL1562666 | 0.80 | CCNA2 (0.47) | CNR2CCNA2CDK2CCNA1MCHR1 | |
| SCHEMBL15134599 | 0.77 | CDK2 (0.53) | CNR2CCNA2CDK2CCNA1MCHR1 | |
| SCHEMBL25450366 | 0.77 | BRD4 (0.44) | MCHR1 | |
| SCHEMBL16142905 | 0.75 | CCNA2 (0.51) | CNR2CCNA2CDK2CCNA1MCHR1 | |
| SCHEMBL15129444 | 0.74 | CNR2 (0.44) | CNR2CCNA2CDK2CCNA1MCHR1 | |
| SCHEMBL25465489 | 0.74 | CYP19A1 (0.38) | — | |
| SCHEMBL14174628 | 0.74 | MAPK8 (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322744-A1 | COMPOUNDS AS GLP-1R AGONISTS | TERNS PHARMACEUTICALS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230150998-A1 | COMPOUNDS AS GLP-1R AGONISTS | Terns, Inc. | 2023-05-18 | — | — | US | disclosed |
| US-20230150998-A1 | COMPOUNDS AS GLP-1R AGONISTS | Terns, Inc. | 2023-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322744-A1 | COMPOUNDS AS GLP-1R AGONISTS | GLP1R, GIPR, GCGR | CNR2 749/4885CCNA2 4876/4885CDK2 3732/4885 |
| US-20230150998-A1 | COMPOUNDS AS GLP-1R AGONISTS | GLP1R, GIPR, GCGR | CNR2 795/4885CCNA2 4872/4885CDK2 4337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.